NEW YORK, November 23, 2016 /PRNewswire/ --
Stock-Callers.com takes another look at the Biotech space, which is engaged in the research and development of biological substances, for the purpose of drug discovery and diagnostic development. Its key regions are Europe and the US, with the latter being the leading industry player worldwide. Four equities have been lined up for assessment this morning: PTC Therapeutics Inc. (NASDAQ: PTCT), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Seres Therapeutics Inc. (NASDAQ: MCRB). You can access of our complimentary research reports on these stocks now at:
At the close on Tuesday, shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc. dropped 3.06%, ending the day at $11.73. The stock recorded a trading volume of 985,038 shares. The Company's shares have surged 75.07% in the last one month and 46.99% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 19.95% and 34.11%, respectively. Moreover, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have a Relative Strength Index (RSI) of 63.03.
On November 14th, 2016, research firm Credit Suisse upgraded the Company's stock rating from 'Neutral' to 'Outperform'.
On November 18th, 2016, PTC Therapeutics announced that on November 17th, 2016, it approved non-statutory stock options to purchase an aggregate of 33,600 shares of its common stock to eight new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the company's new hires' employment compensation. Visit us today and download your complete report on PTCT for free at:
Shares in San Diego, California-based Arena Pharmaceuticals Inc. ended the day 2.58% lower at $1.51 and with a total trading volume of 1.13 million shares. The stock is trading below its 50-day moving average by 7.94%. Shares of the Company, which discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the US and South Korea, have an RSI of 43.39.
On November 07th, 2016, Arena Pharmaceuticals reported that Q3 2016 revenues totaled $19.2 million, including $3.3 million in net product sales of BELVIQ and $11.0 million in milestone payments earned from Eisai for BELVIQ. For the reported quarter net loss attributed to its stockholders was $12.4 million or $0.05 per share. At September 30th, 2016, the company's cash and cash equivalents totaled $101.6 million. The complimentary research report on ARNA can be accessed at:
On Tuesday, shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. finished 5.56% lower at $1.70 with a total trading volume of 481,451 shares. The stock is trading below its 50-day moving average by 26.70%. Shares of the Company, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 20.45.
On November 09th, 2016, BioDelivery Sciences' total net revenue for Q3 2016 was $3.6 million compared to $1.2 million for Q3 2015 and $5.0 million for Q2 2016. The Q2 2016 revenue included a one-time recording of $2.5 million for the upfront payment from Collegium Pharmaceutical for the licensing rights to ONSOLIS® in the U.S. The company's net loss for Q3 2016 was $16.0 million, or ($0.30) per diluted share, compared to a net loss of $20.4 million, or ($0.39) per diluted share in Q3 2015. BioDelivery Sciences had cash and cash equivalents of approximately $44.7 million at September 30th, 2016. Register for free on Stock-Callers.com and download the PDF research report on BDSI at:
Cambridge, Massachusetts headquartered Seres Therapeutics Inc.'s shares recorded a trading volume of 333,778 shares at the end of yesterday's session and closed the day at $10.87, declining 5.40%. The stock is trading below its 50-day moving average by 9.06%. Shares of the Company, which focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome, have an RSI of 40.84.
On November 10th, 2016, Seres Therapeutics reported a net loss of $18.7 million for Q3 2016, compared to a net loss of $14.6 million for Q3 2015. The increase in net loss was driven primarily by continued growth in clinical and development expenses as well as increased headcount, and ongoing development of the Company's microbiome therapeutics platform. The Q3 2016 net loss figure was inclusive of $13.0 million in revenue recognized associated with the Company's collaboration with Nestlé Health Science. Research and development expenses for Q3 2016 were $24.1 million compared to $9.9 million for Q3 2015. Seres ended Q3 2016 with approximately $256.5 million in cash, cash equivalents, and investments. Get free access to your research report on MCRB at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA